{"id":32713,"date":"2017-10-01T11:49:10","date_gmt":"2017-10-01T11:49:10","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=32713"},"modified":"2017-12-19T15:53:02","modified_gmt":"2017-12-19T15:53:02","slug":"pilot-study-of-dolutegravirlamivudine-as-dual-therapy-first-line-art","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/32713","title":{"rendered":"Dual therapy with dolutegravir plus lamivudine as first-line ART"},"content":{"rendered":"

\"\"Simon Collins, HIV i-Base<\/strong><\/p>\n

Results from a US pilot study using dolutegravir plus lamivudine dual therapy in treatment-naive participants reported good early efficacy including with high baseline viral load. [1]<\/strong><\/p>\n

ACTG A5353 was a single-arm, open-label, phase 2 pilot study in 120 participants with viral load <500,000 copies\/mL. Exclusion criteria included active hepatitis B infection or major drug-associated mutations in RT, PI or integrase.<\/p>\n

Baseline characteristics included median age 30 (IQR: 24 to 41) years; 87% male; 40% black, 28% white, 27% Hispanic. Median CD4 count and viral load were 387 (288 to 596) cells\/mm3 <\/sup>and 4.61 (3.94, 5.05) log copies\/mL.<\/p>\n

At week 24, the primary endpoint of viral load <50 copies\/mL was reported for 108\/120 participants (90%CI: 83% to 95%). Response rates were similar when stratified by baseline viral load being above\/below 100,000 copies\/mL, even though baseline characteristics of the >100,000 group (n=37) by definition had higher viral load and lower CD4 counts associated with more advanced HIV infection.<\/p>\n

However, there were more virological failures in the high viral load group: n=3 (8%) vs n=2 (2%). In contrast, failure due to missing data was less common for the high viral load group: n=1 (3%) vs n=6 (7%), though numbers are small.<\/p>\n

Three participants met protocol-defined viral failure linked to low adherence (confirmed by low drug levels), one of whom developed R263R\/K (integrase) and M184V (RT).<\/p>\n

Note: this study was published ahead of press in December 2017. [2]<\/p>\n

Reference<\/p>\n

    \n
  1. Taiwo BO et al. ACTG A5353: A pilot study of dolutegravir (DTG) + lamivudine (3TC) for initial treatment of HIV-1-infected participants with HIV-1 RNA <500,000 copies\/mL. IAS 2017, Paris. Oral abstract TULBPEB21.
    \nhttp:\/\/programme.ias2017.org\/Abstract\/Abstract\/5634
    \n<\/a>    http:\/\/programme.ias2017.org\/\/PAGMaterial\/eposters\/5634.pdf<\/a> (PDF)<\/li>\n
  2. Taiwo BO et al. ACTG A5353: A pilot study of dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA” <500,000 copies\/mL.\u00a0Clinical Infectious Diseases. doi: 10.1093\/cid\/cix1083.
    \n    https:\/\/academic.oup.com\/cid\/advance-article-abstract\/doi\/10.1093\/cid\/cix1083\/4743559<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Simon Collins, HIV i-Base Results from a US pilot study using dolutegravir plus lamivudine dual therapy in treatment-naive participants reported good early efficacy including with high baseline viral load. [1] ACTG A5353 was a single-arm, open-label, phase 2 pilot study …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,3],"tags":[243],"class_list":["post-32713","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-antiretrovirals","tag-ias-9-paris-2017"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/32713","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=32713"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/32713\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=32713"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=32713"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=32713"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}